RBC Capital analyst Brian Abrahams downgraded Ambrx Biopharma (AMAM) to Sector Perform from Outperform with a $28 price target after Johnson & Johnson (JNJ) announced a deal to acquire all of the outstanding shares of Ambrx for $28.00 per share in cash.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AMAM:
- Ambrx Announces Sale to Johnson & Johnson
- Ambrx Biopharma to be added to the Nasdaq Biotechnology Index
- Ambrx to be Added to the NASDAQ Biotechnology Index (NBI)
- Ambrx Biopharma provides update on APEX-01
- Ambrx Provides Update On APEX-01, an On-Going Phase 1 / 2 Dose Escalation Study Evaluating ARX517, a Proprietary PSMA-Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer